Literature DB >> 22539774

Suppression of phosphoinositide 3-kinase signaling and alteration of multiple ion currents in drug-induced long QT syndrome.

Zhongju Lu1, Chia-Yen C Wu, Ya-Ping Jiang, Lisa M Ballou, Chris Clausen, Ira S Cohen, Richard Z Lin.   

Abstract

Many drugs, including some commonly used medications, can cause abnormal heart rhythms and sudden death, as manifest by a prolonged QT interval in the electrocardiogram. Cardiac arrhythmias caused by drug-induced long QT syndrome are thought to result mainly from reductions in the delayed rectifier potassium ion (K(+)) current I(Kr). Here, we report a mechanism for drug-induced QT prolongation that involves changes in multiple ion currents caused by a decrease in phosphoinositide 3-kinase (PI3K) signaling. Treatment of canine cardiac myocytes with inhibitors of tyrosine kinases or PI3Ks caused an increase in action potential duration that was reversed by intracellular infusion of phosphatidylinositol 3,4,5-trisphosphate. The inhibitors decreased the delayed rectifier K(+) currents I(Kr) and I(Ks), the L-type calcium ion (Ca(2+)) current I(Ca,L), and the peak sodium ion (Na(+)) current I(Na) and increased the persistent Na(+) current I(NaP). Computer modeling of the canine ventricular action potential showed that the drug-induced change in any one current accounted for less than 50% of the increase in action potential duration. Mouse hearts lacking the PI3K p110α catalytic subunit exhibited a prolonged action potential and QT interval that were at least partly a result of an increase in I(NaP). These results indicate that down-regulation of PI3K signaling directly or indirectly via tyrosine kinase inhibition prolongs the QT interval by affecting multiple ion channels. This mechanism may explain why some tyrosine kinase inhibitors in clinical use are associated with increased risk of life-threatening arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22539774      PMCID: PMC3494282          DOI: 10.1126/scitranslmed.3003623

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  37 in total

1.  Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity.

Authors:  Yiqiang Zhang; Huizhen Wang; Jingxiong Wang; Hong Han; Stanley Nattel; Zhiguo Wang
Journal:  FEBS Lett       Date:  2003-01-16       Impact factor: 4.124

2.  The phosphoinositide 3-kinase inhibitor LY294002 enhances cardiac myocyte contractility via a direct inhibition of Ik,slow currents.

Authors:  Hui Sun; Gavin Y Oudit; Rafael J Ramirez; Danny Costantini; Peter H Backx
Journal:  Cardiovasc Res       Date:  2004-06-01       Impact factor: 10.787

Review 3.  Drug-induced prolongation of the QT interval.

Authors:  Dan M Roden
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

4.  Differential regulation of the phosphatidylinositol 3-kinase/Akt and p70 S6 kinase pathways by the alpha(1A)-adrenergic receptor in rat-1 fibroblasts.

Authors:  L M Ballou; M E Cross; S Huang; E M McReynolds; B X Zhang; R Z Lin
Journal:  J Biol Chem       Date:  2000-02-18       Impact factor: 5.157

5.  Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome.

Authors:  D Nuyens; M Stengl; S Dugarmaa; T Rossenbacker; V Compernolle; Y Rudy; J F Smits; W Flameng; C E Clancy; L Moons; M A Vos; M Dewerchin; K Benndorf; D Collen; E Carmeliet; P Carmeliet
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death.

Authors:  Peter J Mohler; Jean-Jacques Schott; Anthony O Gramolini; Keith W Dilly; Silvia Guatimosim; William H duBell; Long-Sheng Song; Karine Haurogné; Florence Kyndt; Mervat E Ali; Terry B Rogers; W J Lederer; Denis Escande; Herve Le Marec; Vann Bennett
Journal:  Nature       Date:  2003-02-06       Impact factor: 49.962

7.  Mechanisms by which SCN5A mutation N1325S causes cardiac arrhythmias and sudden death in vivo.

Authors:  Xiao-Li Tian; Sandro L Yong; Xiaoping Wan; Ling Wu; Mina K Chung; Patrick J Tchou; David S Rosenbaum; David R Van Wagoner; Glenn E Kirsch; Qing Wang
Journal:  Cardiovasc Res       Date:  2004-02-01       Impact factor: 10.787

8.  Mechanisms of arsenic-induced prolongation of cardiac repolarization.

Authors:  Eckhard Ficker; Yuri A Kuryshev; Adrienne T Dennis; Carlos Obejero-Paz; Lu Wang; Peter Hawryluk; Barbara A Wible; Arthur M Brown
Journal:  Mol Pharmacol       Date:  2004-07       Impact factor: 4.436

9.  Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.

Authors:  Gary R Mirams; Yi Cui; Anna Sher; Martin Fink; Jonathan Cooper; Bronagh M Heath; Nick C McMahon; David J Gavaghan; Denis Noble
Journal:  Cardiovasc Res       Date:  2011-02-07       Impact factor: 10.787

10.  Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate.

Authors:  J S Mitcheson; J Chen; M C Sanguinetti
Journal:  J Gen Physiol       Date:  2000-03       Impact factor: 4.086

View more
  69 in total

1.  Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs.

Authors:  Dan M Roden
Journal:  Card Electrophysiol Clin       Date:  2014-12-01

2.  Paper reveals new channels for worry over long QT syndrome.

Authors:  Roxanne Palmer
Journal:  Nat Med       Date:  2012-06-06       Impact factor: 53.440

3.  Azithromycin Causes a Novel Proarrhythmic Syndrome.

Authors:  Zhenjiang Yang; Joseph K Prinsen; Kevin R Bersell; Wangzhen Shen; Liudmila Yermalitskaya; Tatiana Sidorova; Paula B Luis; Lynn Hall; Wei Zhang; Liping Du; Ginger Milne; Patrick Tucker; Alfred L George; Courtney M Campbell; Robert A Pickett; Christian M Shaffer; Nagesh Chopra; Tao Yang; Bjorn C Knollmann; Dan M Roden; Katherine T Murray
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-04

Review 4.  A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine.

Authors:  Lars S Maier
Journal:  J Cardiovasc Pharmacol       Date:  2009-10       Impact factor: 3.105

5.  Intracellular ATP binding is required to activate the slowly activating K+ channel I(Ks).

Authors:  Yang Li; Junyuan Gao; Zhongju Lu; Kelli McFarland; Jingyi Shi; Kevin Bock; Ira S Cohen; Jianmin Cui
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-04       Impact factor: 11.205

Review 6.  Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies.

Authors:  Rezarta Cuni; Iris Parrini; Riccardo Asteggiano; Maria Rosa Conte
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

7.  A phosphoinositide 3-kinase (PI3K)-serum- and glucocorticoid-inducible kinase 1 (SGK1) pathway promotes Kv7.1 channel surface expression by inhibiting Nedd4-2 protein.

Authors:  Martin Nybo Andersen; Katarzyna Krzystanek; Frederic Petersen; Sofia Hammami Bomholtz; Søren-Peter Olesen; Hugues Abriel; Thomas Jespersen; Hanne Borger Rasmussen
Journal:  J Biol Chem       Date:  2013-11-08       Impact factor: 5.157

8.  Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes.

Authors:  Joe-Elie Salem; Tao Yang; Javid J Moslehi; Xavier Waintraub; Estelle Gandjbakhch; Anne Bachelot; Francoise Hidden-Lucet; Jean-Sebastien Hulot; Bjorn C Knollmann; Benedicte Lebrun-Vignes; Christian Funck-Brentano; Andrew M Glazer; Dan M Roden
Journal:  Circulation       Date:  2019-08-05       Impact factor: 29.690

9.  MATLAB implementation of a dynamic clamp with bandwidth of >125 kHz capable of generating I Na at 37 °C.

Authors:  Chris Clausen; Virginijus Valiunas; Peter R Brink; Ira S Cohen
Journal:  Pflugers Arch       Date:  2012-12-09       Impact factor: 3.657

10.  Mechanisms of electrical remodeling in lipotoxic guinea pig heart.

Authors:  Ademuyiwa S Aromolaran
Journal:  Biochem Biophys Res Commun       Date:  2019-09-17       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.